Rajasthan govt set to revive Rajasthan Drugs and Pharma

Jaipur:  The government of Rajasthan is set to revive Rajasthan Drugs and Pharmaceuticals Limited (RDPL), a Central Public Sector Undertaking (CPSU) based in the state. RDPL is jointly owned by the Central government, which holds a 51% equity stake, and the Rajasthan state government, which owns the remaining 49%.

The decision to revive RDPL was announced earlier in the budget, and the Department of Medical and Health has begun follow-up measures. As part of this effort, Neha Giri, Managing Director of Rajasthan Medical Services Corporation Limited (RMSCL), recently conducted an inspection of the RDPL.

During the inspection, Giri was accompanied by RDPL’s Special Officer and other officials of the corporation, as per UNI.

She inspected the production area, quality control, storage facilities, main building, and campus of RDPL. She was informed that RDPL is located in an industrial area with approximately 10 acres of land under its possession.

Giri inspected the machines and equipment installed at the RDPL campus and assessed their functionality. She directed the RDPL representative to provide information about the company’s building, equipment, and all liabilities. She also sought information about the pending court cases related to RDPL and gave the necessary instructions.

The MD directed that a report be prepared on the 2016 fire incident at RDPL, as well as a compilation of information about the board of directors, currently employed staff, financial provisions, and all liabilities. She also inspected the water supply, electricity supply, biomedical waste, and designated storage areas within the RDPL campus.

Related Posts

  • Pharma
  • May 15, 2025
  • 53 views
Biolumpivaxin: Bharat Biotech launches new vaccine against lumpy skin disease

Andhra Pradesh chief minister N Chandrababu Naidu on Wednesday launched Bharat Biotech group company Biovet’s new vaccine against the lumpy skin disease (LSD) in dairy cattle and buffaloes, the company…

  • Pharma
  • May 14, 2025
  • 104 views
DTAB asks DCGI to take up withdrawal of license for certain FDC antibiotics with SLAs

The Drugs Technical Advisory Board (DTAB) has directed the Central drug regulator to take up the matter related to withdrawal of product license for antibiotic fixed dose combinations (FDCs), which…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Biolumpivaxin: Bharat Biotech launches new vaccine against lumpy skin disease

Biolumpivaxin: Bharat Biotech launches new vaccine against lumpy skin disease

DTAB asks DCGI to take up withdrawal of license for certain FDC antibiotics with SLAs

DTAB asks DCGI to take up withdrawal of license for certain FDC antibiotics with SLAs

India’s anti-obesity drug market quadruples in five years on lifestyle disease surge

India’s anti-obesity drug market quadruples in five years on lifestyle disease surge

3 held with 60,000 tramadol tablets

3 held with 60,000 tramadol tablets

Indian Pharma May See Limited Short-Term Impact from US Drug Pricing Order

Indian Pharma May See Limited Short-Term Impact from US Drug Pricing Order

Hip Hip No Hurray: Steroid Misuse Linked To Rising Damage In Youths

Hip Hip No Hurray: Steroid Misuse Linked To Rising Damage In Youths